Table 1

Heterogeneity and pooled estimates in primary syntheses and sensitivity analyses

OutcomeQI2 (%)τ2p ValueRR (95% CI)/
MWP (95% CI)
Qual-adj RR (95% CI)Pub bias-adj RR (95% CI)
DoD44.218.60.0070.160.67 (0.62 to 0.72)0.67 (0.63 to 0.71)0.72 (0.68 to 0.76)
DoD ≤12 h9.30.00.0000.580.63 (0.54 to 0.74)
DoD >12 h33.528.50.0100.090.67 (0.62 to 0.73)
DoD IVT3.26.40.0020.360.68 (0.57 to 0.80)
DoD IA/EVT40.921.90.0080.130.67 (0.61 to 0.72)
Mortality45.416.40.0180.180.49 (0.44 to 0.55)0.49 (0.44 to 0.54)0.50 (0.46 to 0.55)
Mortality ≤12 h13.39.80.0230.340.46 (0.35 to 0.60)
Mortality >12 h31.621.00.0190.160.50 (0.44 to 0.56)
Mortality IVT2.040.00.0000.560.53 (0.40 to 0.70)
Mortality IA/EVT43.221.40.0250.130.48 (0.42 to 0.55)
ICH123.365.90.010<0.000113% (10 to 16)14% (13 to 16)No pub bias found
ICH ≤12h23.448.70.0070.0210% (5 to 15)
ICH >12h88.267.10.009<0.000114% (11 to 18)
ICH IVT12.375.70.0110.0069% (2 to 18)
ICH IA/EVT107.664.70.010<0.000114% (10 to 17)
  • DoD, death or dependency; I2, percentage of total variance attributable to heterogeneity; IA/EVT, intra-arterial/endovascular therapy; ICH, intracerebral hemorrhage; IVT, intravenous thrombolysis; MWP, mean weighted probability; p, p value for heterogeneity; Pub bias-adj, publication bias adjusted; Q, Cochran's Q; Qual-adj, quality adjusted; RR, risk ratio; τ2, between study variance.